Loading...
CL logo

Cresco Labs Inc.CNSX:CL Aktierapport

Marknadsvärde CA$673.6m
Aktiekurs
CA$1.49
CA$2.42
38.5% undervärderad intrinsisk rabatt
1Y21.1%
7D8.8%
Portföljens värde
​
Utsikt

Cresco Labs Inc.

CNSX:CL Aktierapport

Börsvärde: CA$673.6m

Cresco Labs (CL) Aktievy

Cresco Labs Inc. odlar, tillverkar och säljer cannabisprodukter för detaljhandel och medicinsk användning i USA. Mer information

CL fundamental analys
Snöflinga Score
Värdering5/6
Framtida tillväxt0/6
Tidigare resultat0/6
Finansiell hälsa3/6
Utdelningar0/6

Belöningar

Handlar till 61.8% under vår uppskattning av dess verkliga värde

Handlas till ett bra värde jämfört med konkurrenter och branschen

Riskanalys

För närvarande olönsamt och förväntas inte bli lönsamt under de kommande 3 åren

Volatil aktiekurs under de senaste 3 månaderna jämfört med Canadian -marknaden

Betydande insiderförsäljning under de senaste 3 månaderna


CL Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 75.3% undervärderad intrinsisk rabatt
5022.2%Revenue growth p.a.
3.7k
23
2
54
29d ago

Cresco Labs Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Cresco Labs
Historiska aktiekurser
Aktuell aktiekursCA$1.49
52 veckors högstaCA$3.12
52 veckors lägstaCA$0.60
Beta1.65
1 månads förändring17.32%
3 månaders förändring4.93%
1 års förändring21.14%
3 års förändring-33.48%
5 års förändring-90.59%
Förändring sedan börsintroduktionen-77.25%

Senaste nyheter och uppdateringar

CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.

CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.

CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook

Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.

Recent updates

CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.

CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.

CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook

Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.

CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook

Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.

CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook

Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).

Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Feb 12
Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook

Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).

CL: New German Entry Will Support Future Upside

Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.

CL: German Entry And Higher Margins Will Support Future Upside

Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).

CL: Expanded Retail And European Entry Will Support Stronger Profitability

Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).

Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%

Nov 26
Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%

Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load

Nov 08
Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load

Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking

Oct 12
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking

Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?

Sep 06
Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?

Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking

Jul 31
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking

Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt

Jul 23
Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt

Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk

Jun 15
Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk

Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up

May 01
Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up
User avatar

Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand

Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%

Mar 07
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%

Is Cresco Labs (CSE:CL) A Risky Investment?

Jan 31
Is Cresco Labs (CSE:CL) A Risky Investment?

Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Dec 14
Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04
Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Aktieägarnas avkastning

CLCA PharmaceuticalsCA Marknad
7D8.8%11.5%0.3%
1Y21.1%46.0%36.6%

Avkastning vs industri: CL presterade sämre än Canadian Pharmaceuticals branschen som gav 46 % under det senaste året.

Avkastning vs Marknaden: CL presterade sämre än Canadian marknaden som gav 36.6 % under det senaste året.

Prisvolatilitet

Is CL's price volatile compared to industry and market?
CL volatility
CL Average Weekly Movement17.4%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement10.6%
10% most volatile stocks in CA Market18.3%
10% least volatile stocks in CA Market4.0%

Stabil aktiekurs: CL s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för Canadian.

Volatilitet över tid: CL s veckovolatilitet ( 17% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av Canadian aktier.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
n/a2,900Charlie Bachtellwww.crescolabs.com

Cresco Labs Inc. odlar, tillverkar och säljer cannabisprodukter för detaljhandel och medicinsk användning i USA. Det tillhandahåller cannabis i blommor, vape-pennor, levande hartser, engångspennor och extrakt under varumärket Cresco; vape-vagnar, vape-pennor, blommor, popcorn, shake, pre-rolls, shorties och koncentrat under varumärket High Supply; vapes och gummier under varumärket Good News; vapes och ätbara produkter under varumärket Wonder Wellness Co.; och tinkturer, kapslar, salvor och sublinguala oljor under varumärket Remedi. Företaget erbjuder cannabisblommor under varumärket FloraCal; och cannabisoljor och olika bett finns tillgängliga på flera styrka nivåer under varumärket Mindy's Edibles, samt licenser varumärket Kiva.

Cresco Labs Inc. Sammanfattning av grunderna

Hur förhåller sig Cresco Labs:s resultat och omsättning till dess börsvärde?
CL grundläggande statistik
BörsvärdeCA$673.60m
Vinst(TTM)-CA$184.05m
Intäkter(TTM)CA$891.44m
0.6x
P/S-förhållande
-3.0x
P/E-förhållande

Är CL övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
CL resultaträkning (TTM)
IntäkterUS$655.85m
Kostnad för intäkterUS$331.28m
BruttovinstUS$324.57m
Övriga kostnaderUS$459.98m
Intäkter-US$135.41m

Senast redovisade vinst

Dec 31, 2025

Nästa vinstdatum

May 08, 2026

Vinst per aktie (EPS)-0.37
Bruttomarginal49.49%
Nettovinstmarginal-20.65%
Skuld/egenkapitalförhållande132.1%

Hur har CL utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/01 22:57
Aktiekurs vid dagens slut2026/05/01 00:00
Intäkter2025/12/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Cresco Labs Inc. bevakas av 13 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Russell StanleyBeacon Securities Limited